{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:06:08Z","timestamp":1783602368018,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007461","name":"Pezcoller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118203","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:59:04Z","timestamp":1748023144000},"page":"118203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Induction of cell death by the CXCR2 antagonist SB225002 in colorectal cancer and stromal cells"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-3700","authenticated-orcid":false,"given":"Chiara","family":"Bazzichetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-9022","authenticated-orcid":false,"given":"Marta","family":"Di Martile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8579-5222","authenticated-orcid":false,"given":"Fabiana","family":"Conciatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118203_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.biopha.2025.118203_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438466","article-title":"State-of-the-art management of colorectal cancer: treatment advances and innovation","volume":"44","author":"Pathak","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8028","key":"10.1016\/j.biopha.2025.118203_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-024-07747-9","article-title":"The genomic landscape of 2,023 colorectal cancers","volume":"633","author":"Cornish","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2025.118203_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"11","key":"10.1016\/j.biopha.2025.118203_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118203_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/oncolo\/oyae152","article-title":"Predictors of response to immunotherapy in colorectal cancer","volume":"29","author":"Gonzalez-Montero","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.biopha.2025.118203_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s42003-020-01263-y","article-title":"BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer","volume":"3","author":"Conciatori","year":"2020","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118203_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102631","article-title":"Interleukin-8 in colorectal cancer: a systematic review and meta-analysis of its potential role as a prognostic biomarker","volume":"10","author":"Bazzichetto","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.biopha.2025.118203_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6606055","article-title":"The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue","volume":"104","author":"Oladipo","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118203_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118203_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","article-title":"The CXCL8-CXCR1\/2 pathways in cancer","volume":"31","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"issue":"41","key":"10.1016\/j.biopha.2025.118203_bib12","doi-asserted-by":"crossref","first-page":"43375","DOI":"10.18632\/oncotarget.6234","article-title":"Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling","volume":"6","author":"Brandolini","year":"2015","journal-title":"Oncotarget"},{"issue":"7989","key":"10.1016\/j.biopha.2025.118203_bib13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118203_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41416-022-02028-6","article-title":"CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer","volume":"128","author":"Piro","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"W1","key":"10.1016\/j.biopha.2025.118203_bib15","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2025.118203_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862806","article-title":"Fibroblast-induced paradoxical PI3K pathway activation in PTEN-competent colorectal cancer: implications for therapeutic PI3K\/mTOR inhibition","volume":"12","author":"Conciatori","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118203_bib17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.bcp.2013.04.011","article-title":"Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor","volume":"85","author":"Goda","year":"2013","journal-title":"Biochem. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118203_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3892\/ol.2024.14393","article-title":"Clinical significance of the CXCL8\/CXCR1\/R2 signalling axis in patients with invasive breast cancer","volume":"27","author":"Stepien","year":"2024","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.biopha.2025.118203_bib19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6605055","article-title":"CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion","volume":"100","author":"Singh","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118203_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmed.2023.09.003","article-title":"CXCR2 chemokine receptor - a master regulator in cancer and physiology","volume":"30","author":"Lazennec","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118203_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020576","article-title":"CXCR1: a cancer stem cell marker and therapeutic target in solid tumors","volume":"11","author":"Molczyk","year":"2023","journal-title":"Biomedicines"},{"issue":"5307","key":"10.1016\/j.biopha.2025.118203_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","article-title":"Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC","volume":"275","author":"Morin","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118203_bib23","first-page":"1","article-title":"Inhibition of IL-8\/CXCR2 signaling axis prevents tumor growth and metastasis in triple negative breast cancer cells","author":"Jeong","year":"2025","journal-title":"Pharmacology"},{"key":"10.1016\/j.biopha.2025.118203_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114658","article-title":"CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells","volume":"190","author":"Kim","year":"2021","journal-title":"Biochem Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.118203_bib25","first-page":"3726","article-title":"Molecular insights into the microtubules depolymerizing activity of the IL-8 receptor B antagonist SB225002","volume":"26","author":"Goda","year":"2022","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118203_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.990285","article-title":"Editorial: non-apoptotic cell death mechanisms and their therapeutic significance","volume":"10","author":"Lopus","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118203_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2023.119432","article-title":"Surveying the landscape of emerging and understudied cell death mechanisms","volume":"1870","author":"Leak","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118203_bib28","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8373","article-title":"Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro","volume":"48","author":"Urbantat","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118203_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.853484","article-title":"The CXCR1\/CXCR2 inhibitor reparixin alters the development of myelofibrosis in the Gata1 (low) mice","volume":"12","author":"Verachi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118203_bib30","doi-asserted-by":"crossref","first-page":"1125948","DOI":"10.3389\/fimmu.2023.1125948","article-title":"Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity","volume":"14","author":"Al Aameri","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118203_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134783","article-title":"SB225002 induces cell death and cell cycle arrest in acute lymphoblastic leukemia cells through the activation of GLIPR1","volume":"10","author":"de Vasconcellos","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.118203_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054572","article-title":"SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro","volume":"8","author":"Du","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.biopha.2025.118203_bib33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41419-019-2076-1","article-title":"p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway","volume":"10","author":"Contadini","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118203_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-018-0820-5","article-title":"Therapeutic potential of combined BRAF\/MEK blockade in BRAF-wild type preclinical tumor models","volume":"37","author":"Del Curatolo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500397X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500397X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:48:09Z","timestamp":1758124089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500397X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"alternative-id":["S075333222500397X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118203","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction of cell death by the CXCR2 antagonist SB225002 in colorectal cancer and stromal cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118203"}}